---
title: "Akeso falls 6% as FDA rejects ivonescimab US filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305915613.md"
description: "Akeso fell 6.06% to HK$58.15 after FDA rejected ivonescimab U.S. filing; Daiwa, Citi and Nomura cut targets or ratings."
datetime: "2026-11-18T05:01:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305915613.md)
  - [en](https://longbridge.com/en/news/305915613.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305915613.md)
generator: "portal-rs"
---

# Akeso falls 6% as FDA rejects ivonescimab US filing

Akeso (9926.HK) fell more than **6%** in Hong Kong trading, last at **HK$58.15**.

The biotechnology industry index fell 2.6% over the same period.

Overseas partner Summit Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the biologics license application of ivonescimab combined with platinum-based chemotherapy for second-line EGFR-mutated non-small cell lung cancer. The FDA noted that while the study met its primary endpoint of progression-free survival, overall survival did not show a statistically significant improvement, rendering the evidence of effectiveness insufficient.

Daiwa cut its price target on the stock to **HK$120** from HK$140, while Citi lowered its target to **HK$163**. Nomura downgraded the shares to Neutral from Buy and reduced its price target to **HK$94**.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**